treatment resistant depression

News

Compass points to strong psilocybin data in depression

Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.

News

J&J adds first new indication for Caplyta since takeover

Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.

News

Consolidation in psychedelics as atai pairs with Beckley

Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.

News

Beckley Psytech's chief scientific and medical officer Dr Rob Conley

Beckley's psychedelic med inches forward in depression

UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

News

Supernus reports less than super data for depression drug

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial.

News

Dr Villy Valcheva, CEO of Dublin, Ireland-based GH Research

GH Research leaps on psychedelic data in depression

After setbacks with psychedelics, phase 2b data with GH Research's GH001 for treatment-resistant depression could lift confidence in the category.

Compass points to strong psilocybin data in depression

J&J adds first new indication for Caplyta since takeover

Consolidation in psychedelics as atai pairs with Beckley

Beckley's psychedelic med inches forward in depression

Supernus reports less than super data for depression drug

GH Research leaps on psychedelic data in depression

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

treatment resistant depression

Editor's Picks